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Abstract
Background: Solitary fibrous tumor is a mesenchymal tumor of fibroblastic type, which can affect any region of the
body. Recently, a recurrent gene fusion NAB2-STAT6 has been identified as molecular hallmark. The NAB2-STAT6
fusion leads to EGR1 activation and transcriptional deregulation of EGR1-dependent target genes and is a driving
event in initiation of SFT. In this study, we report the clinicopathologic and RT-PCR findings and evaluated expression
of STAT6 and EGR1 protein in a cohort of 28 SFTs.
Methods: 28 patients with a median age of 54 years were included with SFTs originating at different sites, most
occurring in the lung and pleura (9, 32%), 5 in soft tissues of the lower extremities (18%) and 5 in the head and neck
(18%). For detection of the NAB2-STAT6 fusion gene, RT-PCR was performed using RNA extracted from formalin-fixed
and paraffin-embedded tissues. Immunohistochemistry was performed on all cases with antibodies against STAT6
and EGR1.
Results: All patients were treated by surgery, 3 with adjuvant chemo- or radiotherapy. Follow-up data of 18
patients could be obtained of which 2 patients died of metastatic disease 13 months and 52 years after first diagnosis.
Sixteen patients have no evidence of disease with a median follow up of 29.5 months (range 7 – 120 months).
NAB2-STAT6 fusion transcripts were found in 19/28 cases (68%). The most common fusion was between NAB2 exon 4
and STAT6 exon 3 (11/19, 58%), mainly occurring in pleuropulmonary lesions. All cases showed strong nuclear expression
of STAT6 (28/28, 100%) while EGR1 showed low-level variable nuclear expression in all samples, comparable with the
EGR1 expression results of the control group.
Conclusions: The identification of the NAB2-STAT6 fusion in SFTs can provide important diagnostic information,
especially in cases with aberrant morphology or when biopsy material is limited. STAT6 immunohistochemistry is
another useful tool in diagnosing SFT. EGR1 immunohistochemistry indicates low-level protein expression in
accordance with EGR1 activation due to distorted NAB2 activity.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_224
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Background
Solitary fibrous tumor (SFT) is a mesenchymal tumor of
fibroblastic type that can affect virtually any region of
the body [1,2]. The neoplastic cells are arranged in a
patternless architecture with alternating hypo- and
hypercellular areas and a prominent branching vascula-
ture. These lesions occur predominantly in middle-aged
adults with equal gender distribution [1]. Most tumors
present as well defined, slow growing masses, which can
be cured by surgery. A small percentage of SFTs, between
10-20%, behave in a more aggressive way, with local recur-
rence and/or distant metastasis for which systemic therapy
(chemotherapy or targeted treatment with e.g. sunitinib)
can be given [1,3-5]. Prediction of behavior is difficult,
with tumor size above 15 cm, positive surgical margins,
tumor site and high mitotic count (>4/10 high power
fields, HPF) being the most useful indicators for malig-
nancy [3,6-8].
Recently, a recurrent gene fusion NAB2-STAT6 has
been identified as molecular hallmark of SFT, encoding
a chimeric protein that combines the EGR-binding domain
of NAB2, a repressor of early growth response (EGR)
transcription factors that regulate differentiation and
proliferation, with the transactivation domain of STAT6,
a transcription factor that mediates cytokine signaling
[2,9]. Molecular detection of the fusion gene and immu-
nohistochemical expression of nuclear STAT6 can be
helpful in diagnosing SFT, especially in cases not un-
equivocally classifiable [2,10-13].
In this study, molecular analysis and immunohisto-
chemical staining of STAT6 protein was performed in 28
cases of SFT. In addition, as the NAB2-STAT6 fusion
leads to EGR1 (early growth response protein 1) activation
and transcriptional deregulation of EGR1-dependent target
genes, we immunohistochemically evaluated the expression
of EGR1 in our tumor samples in order to semi-quantify
EGR1 protein levels in SFT [2,14].
Methods
Tissue samples and immunohistochemistry
Twenty-eight cases were selected from the (referral) files
of the authors between 01–2002 and 08–2014 and slides
were reviewed by two of them (UF, PS). The study was
performed in accordance with the Code of Conduct of
the Federation of Medical Scientific Societies in the
Netherlands. The tissue was fixed in 4% buffered forma-
lin, routinely processed and embedded in paraffin; 4 μm
thick sections were stained with hematoxylin and eosin
and immunohistochemistry was performed using com-
mercially available antibodies listed in Table 1.
Antigen retrieval was performed using EDTA buffer,
pH 9,0 for 10 minutes at 95°C and 10 minutes blocking
with 3% H2O2 in methanol. The primary antibodies
(dilutions presented in Table 1) were added for 1 hour
at room temperature. Secondary antibody Poly-HRP
Gam/R/Ra; Immunologic was applied for 30 minutes
at room temperature. The chromogenic substrate Bright
DAB; Immunologic was applied for 7 minutes at room
temperature.
Cases were scored positive for STAT6, CD34, CD99,
EMA, SMA, Bcl-2 and S100 when at least 50% of tumor
cells showed strong staining. EGR1 was scored using a
six-point scale (0 = negative; 1 = <5% nuclei +; 2 = 5-25%
nuclei +; 3 = 26-50% nuclei +; 4 = 51-75% nuclei +; 5 =
76-100% nuclei +). As (negative) control samples for
STAT6 and EGR1, some possible mimickers of SFT were
stained (5 dedifferentiated liposarcomas, 5 deep benign
fibrous histiocytomas, 5 sarcomatoid mesotheliomas, 7
low grade fibromyxoid sarcomas, 5 schwannomas, 4 ma-
lignant peripheral nerve sheath tumors, 5 gasto-intestinal
stroma cell tumors, 5 synovial sarcomas and 6 leiomyo-
mas). Endothelial nuclei served as an internal positive
control for EGR1. Clinical information, where available,
was obtained from the hospital records.
Reverse transcriptase-Polymerase chain reaction (RT-PCR)
RNA was extracted from formalin-fixed and paraffin-
embedded tissues (FFPE) using RNA-Bee-RNA isola-
tion reagent (Bio-Connect BV, Huissen, the Netherlands)
according to standard procedures. RNA quantity and
quality were determined by a NanoDrop measurement
(Fisher Scientific, Landsmeer, the Netherlands) and subse-
quently, cDNA synthesis was performed using Superscript
II (Invitrogen Life Technologies Europe, Bleiswijk, the
Netherlands) and random hexamers (Promega Nederland,
Leiden, the Netherlands).
The cDNA was tested by the reverse transcription-
polymerase chain reaction (RT-PCR) for the HMBS
(hydroxymethylbilase synthase) housekeeping gene using
the primers forw150 5′-TGCCAGAGAAGAGTGTG
GTG-3′, rev150 5′-ATGATGGCACTGAACTCCTG-3′,
forw250 5′- CTGGTAACGGCAATGCGGCT-3′, rev250
5′- TTCTTCTCCAGGGCATGTTC-3′.
For the detection of the NAB2-STAT6, three primers
in NAB2 (NM_005967.3) exon3 forw 5′- CAAGTAGCC
Table 1 Details of used antibodies
Antibody Clone Dilution Source
STAT6 YE361 1:80 ABCam, Cambridge, UK
EGR1 T.160.5 1:50 ThermoFisher Scientific, Waltham, USA
CD34 QBEnd/10 1:80 Immunologic, Duiven, the Netherlands
CD99 O13 1:150 ThermoFisher Scientific, Waltham, USA
EMA E29 1:250 DAKO, Glostrup, Denmark
SMA 1A4 1:30000 Sigma, Saint Louis, USA
S-100 polyclonal 1:10000 DAKO, Glostrup, Denmark
Bcl-2 124 1:80 DAKO, Glostrup, Denmark
Vogels et al. Diagnostic Pathology 2014, 9:224 Page 2 of 9
http://www.diagnosticpathology.org/content/9/1/224
CGAGAGAGCAC-3′, exon4 forw 5′- CTCCACTGAA
GAAGCTGAAAC-3′ and exon6 forw 5′-CTGTGTGCC
TGCGAAGCC-3′ were used in combination with three
STAT6 (NM_001178078.1) primers: rev 5′-GGGAAAG
TCGACATAGAGCC-3′ (exon3), rev 5′-GAGCTGAGC
AAGATCCCGG-3′ (exon17) and rev 5′-TTCCACGGT
CATCTTGATGG-3′ (exon18). The PCR products were
analyzed by agarose gel electrophoresis. The sequence of
the differently sized PCR-products was obtained by Sanger
sequencing and confirmed presence of the fusion gene.
Results
Clinical data
Clinical data are summarized in Table 2. Twenty-eight
patients were selected, including 10 male and 18 female
patients with an age range of 21–84 years (median,
54 years).
Tumors arose in the lung and pleura (9, 32%), deep
soft tissue of the lower extremities (5, 18%), head and
neck (5, 18%), abdomen (3, 11%) and pelvis (2, 7%).
Other sites were uterus, retroperitoneum, deep soft tis-
sue of the upper extremity and deep soft tissue of the
back (1 case each).
Surgical excision was performed in 28 patients, 1 after
prior embolization. Resection margins were positive in 3
patients, negative in 21 patients, and not reported in 4
cases. One patient with positive margins (case 16) and a
subsequent local recurrence received surgery combined
with radiotherapy for his recurrent disease and had no
evidence of disease at 7 months. The other 2 patients
with positive resection margins did not receive post-
Table 2 Clinical data of 28 patients with SFT
Case Age Sex Size (cm) Site Margin status Treatment Local recurrence MET Follow-up
1 21 F 9 Abdomen Neg SE Y, multiple Y DOD, 52 yrs
2 74 F 9 Calf Neg SE NA NA NA
3 59 M 13 Pelvis Neg SE; CT after MET Y Y NED, MET 48 mo
4 55 F 9.5 Retro-peritoneum Neg SE; CT + RT after MET N Y DOD, 13 mo
5 84 F 10 Para-tracheal Neg SE NA NA NED, 48 mo
6 68 F 17 Lung Neg SE NA NA NA
7 39 F 3 Thigh Neg SE N N NED, 36 mo
8 34 M 4.1 Cheek Neg SE N N NED, 27 mo
9 75 F 12 Neck Neg SE N N NED, 26 mo
10 50 F 10 Uterus Neg SE N N NED, 33 mo
11 52 F 4.7 Biceps Neg SE N N NED, 32 mo
12 52 M 6.3 Lung Pos SE N N NED, 17 mo
13 56 M 16 Pelvis Neg SE N N NED, 12 mo
14 53 F 4.5 Pleura Neg SE N N NED, 21 mo
15 71 M NA Lung NA SE NA NA NA
16 39 M 2 Mastoid Pos EMB + SE; SE + RT
after recurrence
Y N NED, 7 mo after treatment
of recurrent disease
17 44 F 2.5 Orbit Neg SE Y N NA
18 55 M 13 Lung Neg SE N N NED, 9 yrs
19 63 M 4 Lung Neg SE NA NA NA
20 45 F 7.5 Mesenterium Neg SE N N NED, 10 yrs
21 33 F 9 Calf Pos SE N N NED, 23 mo
22 67 F NA Buttock NA SE N N NA
23 68 F 14 Pleura NA SE N N NED, 8 mo
24 76 M 7 Abdomen Neg SE NA NA NA
25 69 F NA Lung NA SE NA NA NA
26 43 M 9.5 Back Neg SE NA NA NA
27 42 F 1.6 Head Neg SE NA NA NA
28 42 F 5.5 Knee Neg SE N N NED, 9 yrs
NA= data not available; SE= surgical excision; MET =metastasis; EMB = embolization; DOD = died of disease; NED = no evidence of disease; AWD = alive with disease;
CT = chemotherapy; RT = radiotherapy; Y = yes; N = no.
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surgical therapy and had no evidence of disease at 17
and 23 months.
Recurrences occurred in 4 instances (14%) including 3
patients with negative margins and the above mentioned
case 16 with positive margins. One of the 3 patients with
negative margins (case 1) had surgical therapy for several
local recurrences and metastatic disease. One patient
(case 3) received surgery for local recurrence and che-
motherapy after discovery of metastatic spread. Fifteen
patients had no recurrences, and of 9 patients, data about
local recurrences were not known.
Metastatic disease occurred in 3 patients, including
case 1 and case 3 mentioned above. One patient (case 4)
received combined radio-chemotherapy after discovery
of metastases. Sixteen patients showed no metastatic dis-
ease and of the remaining 9 cases, data were not known.
Two patients died of metastatic disease 13 months and
52 years after the initial diagnosis (case 4 and 1, respect-
ively). In case 1, recurrences and metastases were histo-
logically proven.
Currently, 16 patients have no evidence of disease with a
median follow up of 29.5 months (range 7 – 120 months),
including 3 patients with long term disease-free follow up.
Ten patients were lost to follow-up or no follow-up data
could be obtained.
Gross findings
Tumor size ranged from 1.6 – 17 cm (median, 9 cm).
Grossly, the tumors had a (multi)nodular configuration
with a coarse white-grayish cut-surface. Myxoid areas
were apparent in some cases.
Microscopic findings
Histologically, most of the tumors were circumscribed
and a (incomplete) pseudo capsule was sometimes
detected. In few cases, focal infiltration of adjacent struc-
tures was seen. All cases showed typical features of SFT
with a patternless architecture of alternating hypo- and
hyper cellular areas of spindle-shaped cells (Figure 1A). A
round cell component was found in 2 cases (case 17 and
recurrences of case 1). The latter case showed additionally
a fascicular growth pattern in the recurrences. The nuclei
were relatively uniform, spindled or oval-shaped. Nuclear
atypia was focally obvious in case 12 and giant cells were
detected in case 8. The mitotic rate ranged from 0/10
HPF to 30/10 HPF (with no differences between patients
with or without metastatic disease, Table 3). Hemangio-
pericytoma-like vessels were visible in all cases, partly with
hyalinization of the vessel walls. A variable collagenous
background was existent and case 5 possessed amianthoid
fibers. Pseudocystic changes were seen in myxoid areas of
5 cases and small areas of necrosis were present in 3 cases.
Mature adipocytes were a component in 1 case being an
example of a morphologically malignant fat-forming SFT
which was published previously [15].
Immunohistochemical findings
Immunohistochemical staining results are summarized in
Table 3 and Table 4. All 28 cases were stained for STAT6
and all of them showed diffuse and strong nuclear positivity
(Figure 2; 28/28, 100%). All 28 cases were stained for EGR1
(Figure 3). Most cases showed less than 25% nuclear posi-
tivity (12/28 cases score 1, 6/28 cases score 2). Few cases
had more than 25% of all nuclei stained (5/28 cases score 3,
1/28 cases score 4, 3/28 cases score 5). Scoring of one case
was not possible due to limited available tissue. All dediffer-
entiated liposarcomas (0/5 pos), deep benign fibrous histio-
cytomas (0/5 pos), sarcomatoid mesotheliomas (0/5 pos),
low grade fibromyxoid sarcomas (0/7 pos), schwannomas
(0/5 pos), malignant peripheral nerve sheath tumors (0/4
pos), gasto-intestinal stroma cell tumors (0/5 pos), synovial
sarcomas (0/5 pos) and leiomyomas (0/6 pos) showed no
nuclear staining for STAT6. EGR1 showed variable expres-
sion in the different tumor samples, as depicted in Table 4.
CD34 (Figure 1B) was positive in 24 of 25 stained
cases (96%) and CD99 in 17 of 18 stained cases (94%).
Bcl-2 showed expression in 100% of the stained samples.
EMA, SMA and S100 were negative in most of the cases
Figure 1 Typical features of SFT visible in all cases (A, HE 10x) and immunohistochemical positive staining of CD34 (B, 10x).
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(83%, 80% and 94%, respectively). One case each was (at least
focally) positive for pan-keratin and desmin (Table 3).
Molecular genetics findings
Results of molecular analysis are summarized in Table 3.
NAB2-STAT6 fusion transcripts were found in 19/28
cases (68%). Most fusions occurred between NAB2 exon
4 and STAT6 exon 3 (11/19, 58%; Figure 4). Nine of
them were detected in lung and pleura lesions. Three
cases (16%) had the isoform NAB2 exon 6 with STAT6
exon 18. Two of them were located in the head and neck
region. Single cases showed fusion variants of NAB2
exon 6 and STAT6 exon 17, NAB2 exon 7 and STAT6
exon 3 and NAB2 exon 6 and STAT6 exon 3. Two tumors
(case 2 and case 8) harbored a fusion, but due to complex
Table 3 Results translocation analysis, mitotic index and immunohistochemical staining
Case Fusion mit. CD34 CD99 EMA SMA S100 BCL2 STAT6 EGR1 Others
1 Ex4-Ex3 8/10 + + - - - + + 1 desmine -
2 Positive 3/10 + + + + + + 3 desmine -, CK-pan -
3 Ex4-Ex3 3/10 + - + + 1 desmine -
4 Negative 0/10 - + - + - + + 1 desmine -
5 Ex4-Ex3 0/10 + + - - + + 1 desmine -, CK-pan -
6 Ex4-Ex3 4/10 + w+ - + + 2 CK-pan +
7 Negative 1/10 + + - - - + + 5 CK-pan -
8 Positive 0/10 + + - + + 2 CK-pan -
9 Ex7-Ex3 0/10 + + + + 2 CK-pan -
10 Negative 1/10 + + - - - + + 3 desmine -, CK-pan -
11 Negative 0/10 + + - - + + 2 desmine -, CK-pan -
12 Ex4-Ex3 1/10 + + + 4 desmine -
13 Negative 0/10 + + f+ - - + + 3 desmine -
14 Ex4-Ex3 0/10 + + + + 1
15 Ex4-Ex3 0/10 + + - - w+ + NA
16 Ex6-Ex17 30/10 + + + + 3 desmine -
17 Ex6-Ex18 13/10 + + - - + + 1 desmine -, CK-pan -
18 Ex4-Ex3 0/10 + - - + + 2 desmine f+, CK-pan -
19 Ex4-Ex3 0/10 + - - + 1 desmine -
20 Negative 1/10 + - - + 1 desmine -, CK-pan -
21 Ex6-Ex18 0/10 + + + 1
22 Ex6-Ex3 0/10 + w+ - + 1 desmine -
23 Ex4-Ex3 8/10 + + - - + + 1 desmine -
24 Negative 1/10 + + + + 3 desmine -, CK-pan -
25 Ex4-Ex3 1/10 + + 1
26 NA 0/10 + + 5
27 Ex6-Ex18 0/10 + + 2
28 NA 6/10 + - - + 5 desmine -, CK-pan -
Mit., mitotic figures/10 HPF; w+, weakly positive; f+, focally positive; NA = not assessable EGR1: 0 = negative; 1 = <5% nuclei +; 2 = 5-25% nuclei +; 3 = 26-50%
nuclei +; 4 = 51-75% nuclei +; 5 = 76-100% nuclei +.
Fusion-positive cases are characterized by exon junctions, except for case 8 showing a complex junction indicated as positive; negative, no fusion detected.
Table 4 Immunohistochemical staining results control
samples
Soft tissue tumor EGR1 STAT6 (pos/total (%))
Dedifferentiated liposarcoma 1,2,3,3,3 0/5 (0%)
Low grade fibromyxoid sarcoma 1,2,2,2,2,3,3 0/7 (0%)




(Sarcomatoid) mesothelioma 1,2,2,3,3 0/5 (0%)
Schwannoma 2,3,3,3,4 0/5 (0%)
Gastro-intestinal stroma cell tumor 2,3,3,4,4 0/5 (0%)
Synovial sarcoma 2,3,3,3,4 0/5 (0%)
Leiomyoma 1,1,2,2,2,3 0/6 (0%)
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breakpoints with a possible inversion the exact exons
could not be verified. In 7 tumors, no NAB2-STAT6 fusion
was found (7/28, 25%). In case 26 and case 28, adequate
interpretation of RT-PCR results was not possible due to
the presence of complex breakpoints.
Discussion
In 1942 and 1949, Stout and Murray defined hemangio-
pericytoma as a neoplasm with prominent branching
vessels surrounded by pericytic tumor cells [16,17]. The
lesions included in their studies comprised true pericytic
tumors, nowadays termed myofibroma/myopericytoma,
and conventional hemangiopericytoma, which was after-
wards accepted as cellular variant of SFT [18]. The unified
entity SFT now also contains the lipomatous variant, giant
cell angiofibroma, and at the malignant end, dedifferen-
tiated SFT showing abrupt transition from classical areas
into high-grade sarcoma [1].
With the advent of whole-genome sequencing, the
fusion gene NAB2-STAT6 has been detected as the driver
mutation of SFT [2,9,10,14]. NAB2 and STAT6, adjacent
genes on 12q13, fuse following genomic inversion of
STAT6 with consecutive transcription in a common dir-
ection [2,9]. Expression of the chimeric protein NAB2-
STAT6 leads to activation of EGR-mediated signaling
via distorted NAB2 activity. Modulation of STAT6 depen-
dent gene expression seems to be an alternative mechan-
ism but was shown to play a minor role [2,9].
NAB2-STAT6 fusion is a distinct molecular feature
of SFT since it has not been detected in other tumors
(so far) and its frequency ranges from 55% to 100%,
irrespective of dignity [2,9,13,14]. There are several
fusion variants, with conjunction of NAB2 exon 4 - STAT6
exon 3 and NAB2 exon 6- STAT6 exon 17 being the most
common [2,13,14]. In our study, 68% of SFTs carried a
NAB2-STAT6 fusion transcript, mostly with a fusion be-
tween NAB2 exon 4 and STAT6 exon 3 in accordance
with the results by Mohajeri et al. and Barthelmess et al.
[13,14]. Negativity for this fusion in 25% of our cases
could possibly be explained by alternative or complex
genetic rearrangements involving other exons or inver-
sions and deletions, not detectable with our primer
combination. In 2 cases (7%), adequate interpretation of
RT-PCR results was not possible due to the presence of
complex breakpoints. Furthermore, in single cases other
fusion genes have been reported, e.g. STAT6-TRAPPC5
[14] and probably additional fusion genes will be de-
tected in the future.
Doyle et al. demonstrated nuclear expression of STAT6
in 98% of a large series of SFTs indicating the presence of
the NAB2-STAT6 fusion protein in the nucleus [11].
STAT6 is therefore a highly sensitive and specific immu-
nohistochemical marker for SFT [10-13,19,20]. This is in
concert with our results, where 100% of the cases showed
strong and diffuse nuclear positivity for STAT6 in
comparison to the control group being 100% negative.
Thereby, STAT6 was diffusely expressed in 7 tumors with-
out a detected NAB2-STAT6 fusion, suspecting limitations
in our RT-PCR approach in which NAB2-STAT6 fusions
could be missed as mentioned above. Potential diagnostic
pitfalls could be STAT6 expression in, for example, the
morphologic mimics deep benign fibrous histiocytoma
and dedifferentiated liposarcoma, especially in retroperi-
toneal and abdominal localization [11]. As known, MDM2
and CDK4 immunohistochemistry or MDM2 FISH are
useful in identifying dedifferentiated liposarcoma. Expres-
sion of STAT6 in ca. 10% of dedifferentiated liposarcomas
is based on amplification of the corresponding gene located
in proximity to MDM2 and CDK4 [11,12,21,22]. Deep be-
nign fibrous histiocytoma may also show a hemangiopericy-
toma-like vasculature and may express CD34 [1]. In such
cases, molecular analysis of NAB2-STAT6 may be helpful.
Figure 3 Low level variable expression of EGR1 was seen in all
samples (20x).
Figure 2 Immunohistochemical staining of STAT6 showing
nuclear positivity in all cases (20x).
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Other differential diagnoses and their histopathological
characteristics are listed in Table 5.
Previously, CD34, CD99 and bcl-2 were the most use-
ful positive immunohistochemical markers for SFT.
However, they are less specific and absence of CD34 does
not rule out SFT [1,28-31].
As expected, CD34, CD99 and bcl-2 were positive in
most of our cases. Case 4 with negative staining for
CD34 and absence of a detectable gene fusion showed
strong nuclear expression of STAT6 and no MDM2
amplification, so the possibility of being a dedifferentiated
liposarcoma was ruled out.
Cell line experiments supported that in contrast to the
known transcriptional repressor activity of NAB2, the
NAB2-STAT6 fusion protein leads to activation of EGR1
and expression of its target genes. In addition, the in-
creased proliferation of the NAB-STAT6-expressing cell
lines could be inhibited by small interfering RNA (siRNA)
knockdown of EGR1 expression [2]. This prompted us to
investigate EGR1 protein expression in our tumor
samples which showed low-level variable nuclear re-
activity in all stained samples, including 47 control
samples of possible mimickers of SFT. This result is in
line with EGR1 protein activation without high-level ex-
pression mainly due to altered NAB2 function resulting in
deregulation of target genes as mentioned above [2,14].
Correlation of clinicopathologic parameters and out-
come is difficult. This could be due to, at least in part,
relatively small cohorts of SFT studied. Therefore, no stat-
istical correlation could be made between pathological
findings and clinical data. To date, no definitive markers
have been identified that classify malignant SFT. Recently,
efforts have been made to define a risk assessment model
based on patient age, tumor size and mitotic index with
promising results [7,8]. From the genetic point of view,
Mohajeri et al. [14] did not find any clinical associations
including genetic changes beyond the fusion-genes. In
contrast, Barthelmess et al. showed that the most com-
mon fusion variant NAB2 exon 4-STAT6 exon 3 corre-
sponded to classic pleuropulmonary SFT as we found in
our study: all 9 pleuropulmonary SFTs had a fusion be-
tween NAB2 exon 4 and STAT6 exon 3.
NAB2 exon 6-STAT6 exon16/17 fusions were detected
in cellular soft tissue SFTs with more aggressive behavior
in younger patients [13].
Three of the 18 patients (17%) of whom we had ad-
equate clinical follow-up data (cases 1, 3, 4) behaved in a
malignant fashion with metastases. Only one of them
showed a high mitotic index (case 1). Locations were ab-
domen, pelvis and retroperitoneum in accordance with
known parameters for malignant potential but sizes were
below 10 cm [6-8].
Therapeutic options for more advanced or aggressive
tumors are scarce and no standard modality for metasta-
sized SFT has currently been accepted. Few chemothera-
peutical drugs have been studied with different outcome.
Anti-angiogenic targeted treatment shows interesting
results [4,5]. The potential role of EGR1 and its down-
stream targets in treatment of (metastasized SFT) is not
clearly defined so far [2,9].
Figure 4 Sequence of the RT-PCR product shows a fusion between exon 4 of NAB2 and exon 3 of STAT6 in the chimeric transcript of
12 cases.
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Conclusions
In summary, STAT6 immunohistochemistry is a powerful
tool in diagnosing SFTs. Also, the identification of the
NAB2-STAT6 fusion gene can provide important diagnostic
information, even in formalin-fixed and paraffin-embedded
tissue or when biopsy material is limited. In accordance
with Barthelmess et al., the most common fusion variant
NAB2 exon 4-STAT6 exon 3 corresponded mostly to
pleuropulmonary SFT.
EGR1 immunohistochemistry indicates low-level pro-
tein expression in accordance with EGR1 activation due to
distorted NAB2 activity resulting in deregulation of EGR1
target genes.
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Table 5 Differential diagnoses of SFT (in accordance with Fletcher et al. and Doyle et al. [1,11])
Histopathological characteristics IHC Genetic alterations
Dedifferentiated liposarcoma lipogenic component with atypia MDM2 +, CDK4 + amplification MDM2
atypia in dediff. component can be mild STAT6 −/+
Deep benign fibrous histiocytoma storiform or short fascicles,
branching vasculature
CD34 +/−, SMA f+/−,
STAT6 −/+
Spindle cell lipoma short stubby nuclei, ropey collagen CD34+ RB1deletion
variable proportions of fat
Cellular angiofibroma short stubby nuclei, wispy collagen CD34 +/−, desmin −/+ RB1 deletion
numerous (hyalinized) vessels SMA −/+,
Mammary type myofibroblastoma (long) fascicles, short stubby nuclei CD34 +, desmin + RB1 deletion
broad bands collagen SMA −/+,
Myofibroma biphasic, immature spindle cells and
mature myoid cells, bluish matrix,
branching vessels
SMA +/−, desmin −/+,
CD34 −/+
Dermatofibrosarcoma protuberans storiform, short fascicles, uniform spindle cells,
“honeycomb” appearance of fat
CD34 + COL1A1-PDGFB
Monophasic synovial sarcoma cellular fascicles, uniform spindle cells TLE1 +, EMA +, CK + SYT-SSX1/2
Cellular schwannoma short bundles, interlacing fascicles S100 + NF2 mutations
tapered nuclei, hyalinized (ectatic) vessels
Perineurioma storiform, whorled growth, bipolar cells,
uniform oval or tapering nuclei
CD34 +/−, EMA +,
Claudin-1−/+, GLUT1 −/+
Low-grade fibromyxoid sarcoma alternating hypo- and more cellular
fascicles and whorls, fibrous and myxoid
background, bland spindle cells
MUC4 +, EMA + FUS-CREB3L1/2
Inflammatory myofibroblastic tumor fascicles of myofibroblasts, myxoid or SMA +/−, desmin +/− ALK rearrangement +/−
collagenous background, inflammation ALK +/−
Sarcomatoid mesothelioma fascicles or haphazard distribution,
atypical spindle cells
CK, EMA, D2-40, caretinin, WT1 BAP1 mutation [23]
Inflammatory fibroid polyp onion-skin pattern, short fascicles CD34 +/− PDGFRA mutation
of the GI tract [24] cells, prominent vasculature, inflammatory
especially eosinophils
Soft tissue angiofibroma [25] variably collagenous and myxoid areas EMA +/−, CD34 −/+ GTF2I-NCOA2 [26]
numerous small branching capillaries AHRR-NCOA2 [27]
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